( Company Conference Call Scheduled for F...)Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting,Health

SAN FRANCISCO, May 03, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that new data from the mild and moderate subgroups of Alzheimer's disease patients in the Company's six-month Phase 2 efficacy study of Dimebon showed that both subgroups were improved compared with placebo-treated patients on all five efficacy endpoints studied.

The mean drug-placebo differences at week 26 on the ADAS-cog, the study's primary endpoint, were 2.4 and 5.8 points in the mild and moderate populations, respectively. The overall response rate to Dimebon treatment (percentage of treated patients showing improvement or no change on the CIBIC- plus at week 26) was 81 percent; the mild subgroup had an 84 percent response rate (42 percent improvement and 42 percent no change) and the moderate subgroup had a 77 percent response rate (45 percent improvement and 32 percent no change).

The Company will host a teleconference with David Hung, M.D., Medivation's president and chief executive officer, Lynn Seely, M.D., Medivation's chief medical officer, and Rachelle Doody, M.D., Ph.D., lead investigator for the study, on Friday, May 4, at 9 a.m. Eastern time to discuss the data.

"In this six-month trial, Dimebon probably improved the clinical course of both mild and moderate Alzheimer's disease patients compared to placebo, results I believe to be promising," said Dr. Doody, who holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston. "These improvements were seen consistently across all outcome measures -- cognition, behavior and activities of daily living -- as well as in the independent CIBIC-plus, a measure of global function."

"Forty-four percent of Dimebon patients were improved compared to baseline as assessed by the CIBIC-p
'"/>